This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
VABYSMO is the first and only FDA-approved treatment designed to block 2 causes of vision loss (VEGF and Ang-2†)
VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO).
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
†The benefit of blocking Ang-2 has not been fully determined. Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
M-PK-00001980
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
Please be aware that you are leaving this website.